Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $64.00 price target on the stock.
Forte Biosciences to Host R&D Day December 3, 2024
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update